Literature DB >> 8582418

Fibrodysplasia ossificans progressiva: still turning into wood after 300 years?

G Buyse1, J Silberstein, N Goemans, P Casaer.   

Abstract

Fibrodysplasia ossificans progressiva (FOP), a rare autosomal dominant disorder, is characterized by symmetrical congenital skeletal abnormalities and progressive heterotopic ossification of the connective tissues. At present, more than 300 years after the first report by Patin in 1648 in which he described the woman who "turned to wood", its pathogenesis remains largely unknown and its therapy is limited to symptom-modifying trials. However, significant progress has been recently made and new data on the molecular organization and regulation of normal and disordered bone induction are likely to lead to a more specific therapy. FOP is believed to be a genetic disorder characterized by a disturbed expression of the endochondral osteogenesis programme, and the remarkable "clues from the fly" reported by Kaplan et al. [8] in 1990 suggest a gain-of-function mutation in the genetic regulation of bone morphogenetic proteins.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8582418     DOI: 10.1007/bf02276711

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  24 in total

Review 1.  Fibrodysplasia ossificans progressiva: a clue from the fly?

Authors:  F S Kaplan; J A Tabas; M A Zasloff
Journal:  Calcif Tissue Int       Date:  1990-08       Impact factor: 4.333

2.  Bone: formation by autoinduction.

Authors:  M R Urist
Journal:  Science       Date:  1965-11-12       Impact factor: 47.728

3.  The hand and foot malformations in fibrodysplasia ossificans progressiva.

Authors:  H W Schroeder; M Zasloff
Journal:  Johns Hopkins Med J       Date:  1980-08

4.  Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients.

Authors:  J M Connor; D A Evans
Journal:  J Bone Joint Surg Br       Date:  1982

5.  Human BMP sequences can confer normal dorsal-ventral patterning in the Drosophila embryo.

Authors:  R W Padgett; J M Wozney; W M Gelbart
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

6.  Chromosomal assignment of the human gene for bone morphogenetic protein 4.

Authors:  J A Tabas; G V Hahn; R B Cohen; H N Seaunez; W S Modi; J M Wozney; M Zasloff; F S Kaplan
Journal:  Clin Orthop Relat Res       Date:  1993-08       Impact factor: 4.176

7.  [Fibrodysplasia ossificans progressiva in a 2-year-old girl].

Authors:  A A Verberne; C F Bos; M C Kuethe
Journal:  Tijdschr Kindergeneeskd       Date:  1988-08

8.  Drosophila hedgehog acts as a morphogen in cellular patterning.

Authors:  J Heemskerk; S DiNardo
Journal:  Cell       Date:  1994-02-11       Impact factor: 41.582

9.  Spinal deformity in patients who have fibrodysplasia ossificans progressiva.

Authors:  P B Shah; M A Zasloff; D Drummond; F S Kaplan
Journal:  J Bone Joint Surg Am       Date:  1994-10       Impact factor: 5.284

10.  A bone morphogenetic protein subfamily: chromosomal localization of human genes for BMP5, BMP6, and BMP7.

Authors:  G V Hahn; R B Cohen; J M Wozney; C L Levitz; E M Shore; M A Zasloff; F S Kaplan
Journal:  Genomics       Date:  1992-11       Impact factor: 5.736

View more
  9 in total

1.  Fibrodysplasia ossificans progressiva without characteristic skeletal anomalies.

Authors:  Hasan Ulusoy
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

Review 2.  GNAS mutations and heterotopic ossification.

Authors:  Murat Bastepe
Journal:  Bone       Date:  2017-09-06       Impact factor: 4.398

3.  BMP type I receptor inhibition reduces heterotopic [corrected] ossification.

Authors:  Paul B Yu; Donna Y Deng; Carol S Lai; Charles C Hong; Gregory D Cuny; Mary L Bouxsein; Deborah W Hong; Patrick M McManus; Takenobu Katagiri; Chetana Sachidanandan; Nobuhiro Kamiya; Tomokazu Fukuda; Yuji Mishina; Randall T Peterson; Kenneth D Bloch
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440

4.  Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.

Authors:  Jian-Kang Jiang; Xiuli Huang; Khalida Shamim; Paresma R Patel; Arthur Lee; Amy Q Wang; Kimloan Nguyen; Gregory Tawa; Gregory D Cuny; Paul B Yu; Wei Zheng; Xin Xu; Philip Sanderson; Wenwei Huang
Journal:  Bioorg Med Chem Lett       Date:  2018-09-06       Impact factor: 2.823

Review 5.  The role of bisphosphonates in diseases of childhood.

Authors:  Tarak Srivastava; Uri S Alon
Journal:  Eur J Pediatr       Date:  2003-09-11       Impact factor: 3.183

6.  Fibrodysplasia ossificance progressiva: A familial presentation.

Authors:  Shwetal Uday Pawar; Sarita Sahoo; Ashmi Manglunia; Gundu Hari Tilve
Journal:  Indian J Nucl Med       Date:  2015 Jul-Sep

7.  Myositis ossificans progressive: case report.

Authors:  Sofia Talbi; Nassira Aradoini; Iman El Mezouar; Fatima Ezzahra Abourazzak; Taoufik Harzy
Journal:  Pan Afr Med J       Date:  2016-07-21

8.  Application of in vitro Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

Authors:  Elias C Padilha; Jianyao Wang; Ed Kerns; Arthur Lee; Wenwei Huang; Jian-Kang Jiang; John McKew; Abdul Mutlib; Rosangela G Peccinini; Paul B Yu; Philip Sanderson; Xin Xu
Journal:  Front Pharmacol       Date:  2019-04-24       Impact factor: 5.810

9.  MYOSITIS OSSIFICANS PROGRESSIVA: CASE REPORT.

Authors:  Frederico Barra de Moraes; Alano Ribeiro de Queiroz Filho; Leonardo Jorge da Silva; Válney Luiz da Rocha; Nayara Portilho Araújo; Ernesto Quaresma Mendonça; Érica Paiva de Almeida
Journal:  Rev Bras Ortop       Date:  2015-12-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.